Clover Health Investments Corp (CLOV)

[KJAX]

"We’re delighted to have delivered our first quarterly Adjusted EBITDA profit as a public company,” said Clover Health CEO Andrew
Toy.

Clover Health Reports Strong Second Quarter 2023 Results; Highlights Improved Financial Performance and Guidance
Ranges
Insurance revenue grew 17% compared to Q2'22, and second quarter Insurance MCR improved to 77.2%, bringing first half MCR to
81.9%
Company reports Q2 Net Loss of $28.8 million, and Adjusted EBITDA profit of $10.0 million
Improved 2023 guidance includes Insurance MCR of 83% - 85%, and Adjusted EBITDA of ($70) million - ($120) million
FRANKLIN, Tenn. - August 8, 2023 – Clover Health Investments, Corp. (NASDAQ: CLOV) ("Clover," "Clover Health" or the
"Company"), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, today
reported financial results for the second quarter 2023. Management will host a conference call today at 5:00 p.m. ET to discuss its
operating results and other business highlights.
For the second quarter 2023, the Company reported revenue of $513.6 million and net loss of $28.8 million. Adjusted EBITDA in the
second quarter 2023 improved to a gain of $10.0 million compared to the second quarter 2022 loss of $83.9 million. Compared to the
second quarter 2022, Insurance revenue grew by 17% to $314.4 million, and MCR improved to 77.2% from 92.1%. As contemplated
in the Company's previously disclosed strategic shift for the Non-Insurance segment, Non-Insurance revenue declined by 67% to $193.5
million, and MCR improved to 99.6% from 106.0%.
"We’re delighted to have delivered our first quarterly Adjusted EBITDA profit as a public company,” said Clover Health CEO Andrew
Toy. “We have been strategically focused on demonstrating the strength of our model by maturing operations, driving efficiencies, and
continuing to invest in Clover Assistant R&D and our home care capabilities. We have multiple exciting initiatives in each of these
areas that we expect will allow us to maintain our momentum through the second half of the year and into 2024. We are reflecting that
expectation via significantly improved full year 2023 guidance for the Insurance segment and on a consolidated basis."
"Insurance MCR improved by more than 1,400 basis points and Non-Insurance MCR improved by more than 600 basis points,
demonstrating the strength of our strategy and our ability to make strides towards sustainable profitability,” said Clover Health CFO
Scott Leffler. “We are excited about our improved outlook for 2023, the favorable impact on our liquidity position, and are also
increasingly confident in the Company’s potential to deliver profitability on an Adjusted EBITDA basis for full year 2024 without the
necessity of raising additional capital."
https://investors.cloverhealth.com/static-files/3731b516-6961-45d8-aba6-7509a4b31791